All Articles

Real-world data showed that patients with metastatic breast cancer receiving palbociclib had a numerically higher rate of neutropenia than patients receiving ribociclib.

The totality of evidence generated from comparative systematic stepwise assessment of HD201 and trastuzumab reference in terms of analytical, pharmacodynamic, pharmacokinetic, and clinical similarity demonstrated the equivalence of HD201 to trastuzumab.

Population-based study results support the use of the neoadjuvant chemotherapy + pertuzumab + trastuzumab biosimilar SB3 treatment regimen in the real-world setting, with responses comparable with those achieved in clinical trials.

Whether called New Year’s resolutions or personal goals, the beginning of a new year is a time for personal reflection and an opportunity to make positive changes in our lives and set our focus on new achievements.

Each year, at the AONN+ annual conference, we pause to take note of the navigators and organizations among us who have made a significant impact in the field of oncology navigation. Although virtual, 2020 was no different, and it was with pride that we announced the 2020 class of AONN+ Award recipients. It is the distinct honor of the JONS Editorial Board and the AONN+ Leadership Council to recognize the navigators and organizations in our community who have made considerable contributions to our chosen specialty. This class of awardees includes a stellar group of navigators and organizations, each with their own unique and inspiring stories. Below, we tell their stories in the hope it provides inspiration to you in your professional life as an oncology nurse navigator or a patient navigator.

The authors share results of their study to contribute to the growing literature about SCPs.

The essential guide to leveraging the value of navigation. Is your institution receiving the ultimate benefits of a navigation program?

Bret Miller is a 10-year breast cancer survivor, and he’s a guy. This is his story.

When it comes to cancer care, organizations tend to define value in terms of objective factors like efficacy, toxicity, and cost. But according to Elizabeth Franklin, PhD, MSW, executive director of the Cancer Policy Institute at the Cancer Support Community in Washington, DC, patients tend to define value differently when it comes to their care.